Bruker Announces Agreement to Acquire Neurescence Inc., Bolstering Neuroscience Research Portfolio
November 14 2022 - 7:00AM
Business Wire
Delivers Simultaneous Multi-Region Neural
Imaging of Free-Behaving Animals
Bruker Corporation (Nasdaq: BRKR) today announced the signing of
the definitive agreement to purchase 100% of the shares of
Neurescence Inc., an innovative provider of ultralight fiber-bundle
Multiscopes™ for simultaneous multi-region, optical functional
neuroimaging. Neurescence’s flagship product Chromatone™ moves
illumination and detection hardware off the animal head. This
enables simultaneous imaging and stimulation of three sub-types of
neurons in up to four regions for flexible investigation of the
central nervous system with single-neuron resolution in
naturalistic behavior. This platform creates strong synergies with
Bruker’s existing Ultima multiphoton solutions and newly acquired
Inscopix head-mounted miniscopes. Financial details of the
agreement were not disclosed.
“Our differentiated system provides a viable means of performing
multi-region-of-interest investigation with minimal weight impact
to subject animals,” said Dr. Yasaman Soudagar, Co-Founder and CEO
of Neurescence. “Now, with Bruker, we can greatly increase the
worldwide reach of this technology to enable researchers to gain
deeper knowledge of neural network functions.”
“Along with our recent addition of Inscopix, this acquisition
bolsters Bruker’s position as the leading provider of freely
behaving animal imaging and photostimulation,” added Dr. Mark R.
Munch, Bruker NANO Group President. “Neurescence’s extremely
flexible and light-weight fiber-bundle Multiscope™ with off-animal
approach has great potential to address diversified research needs
and future trends, opening the door to advanced imaging
modalities.”
About Neurescence Inc. Based in Toronto, Canada, Neurescence was
founded in 2015 by a team of scientists dedicated to developing
better methods for studying the central nervous system. The company
holds recent patents for simultaneous multi-region optical imaging
and stable detachable fiber-lens connectors with a focus lock
mechanism. Neurescence’s Chromatone system enables in vivo calcium
imaging and optogenetics across multiple brain and spinal cord
regions, at single-cell resolution. The use of a detector that is
off-animal enables both higher frame rate capture and the use of
more sensitive cameras. Neurescence combines this novel optical
imaging technology with machine learning to overcome critical
challenges in neuroresearch. Learn more at www.neurescence.com.
About Bruker Corporation (Nasdaq: BRKR) Bruker is
enabling scientists to make breakthrough discoveries and develop
new applications that improve the quality of human life. Bruker’s
high-performance scientific instruments and high-value analytical
and diagnostic solutions enable scientists to explore life and
materials at molecular, cellular, and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
improved productivity, and customer success in life science
molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221114005434/en/
Investors: Justin Ward Senior Director, Investor
Relations & Corporate Development T: +1 (978) 663-3660 x1479 E:
Investor.Relations@bruker.com
Media: Stephen Hopkins Content Marketing Manager T: +1
(520) 741-1044 x1022 E: steve.hopkins@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024